2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

degrader-antibody conjugates

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-129938
    GNE-987 GSH linker-1

    		PROTAC-Linker Conjugates for PAC Cancer
    GNE-987 GSH linker-1, a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 (HY-129937A) and disulfide-containing linker. GNE-987 GSH linker-1 remains inactive as a degrader until intracellular release of GNE-987 via disulfide reduction and linker self-immolation. GNE-987 GSH linker-1 can be used for the research of acute myeloid leukemia .
    GNE-987 GSH linker-1
  • HY-164995
    L1BC8

    		PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC Cancer
    L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .
    L1BC8
  • HY-159665
    CDLI-5

    		E3 Ligase Ligand-Linker Conjugates Cancer
    CDLI-5 is a cereblon degrader-linker conjugate, and can be used for synthesis of cereblon degrader antibody conjugates (cDACs) .
    CDLI-5
  • HY-183939
    L1-CIDE-BRM1-13

    		PROTAC-Linker Conjugates for PAC Others
    L1-CIDE-BRM1-13 (Compound 15) is a linker-drug precursor moiety formed by the covalent conjugation of a PROTAC degrader with a linker for degrader-antibody conjugates (DACs). L1-CIDE-BRM1-13 can be used for the synthesis of DACs .
    L1-CIDE-BRM1-13
  • HY-P9S0124
    Anti-CD33 Antibody (OR000283)

    ORM-6151 antibody; BMS-986497 antibody

    		 Cancer
    Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab (HY-P99971) onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 (HY-171792) .
    Anti-CD33 Antibody (OR000283)
  • HY-182813
    MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885

    		Drug-Linker Conjugates for ADC Cancer
    MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 is a Drug-Linker Conjugates for ADC composed of CC-885 (HY-101488) and a linker. MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 conjugates with GemtUZUmab (HY-P99971) to synthesize an ADC (Compound ADC-2). ADC-2 exhibits anti-tumor activity in a leukemia MV-4-11 xenograft model .
    MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: